With Congress stuck, the administration holds the key to whether Americans will see meaningful reductions in prescription drug costs. So far, though, they’ve punted.
prescription drugs
Posted inBooks
The Pain Profiteers
Two new books reveal the distortion of the U.S. health care system by financial operators.
Posted inHealth and Social Policy
Where’s the Congressional Champion on Pharma Patent Abuses?
Drug companies are using intellectual-property laws to price-gouge the public, and even Republicans don’t like it.
Posted inHealth and Social Policy
Insulin Bill Won’t Help Many Insulin Patients
A proposed cap on co-payments won’t do anything for those without insurance.
Posted inCoronavirus
U.S., EU Back Pharma in Denying Access to Lifesaving COVID Products
A compromise effort to waive intellectual-property rights for vaccines, treatments, and tests will do little to expand supply, experts believe.
Posted inBuilding Back America
Oh No, Joe Manchin’s Talking About a Deal Again
The umpteenth iteration of what Manchin wants out of the Biden agenda is here: some energy investments, paid for by tax and prescription drug reform.
Posted inHealth and Social Policy
Biden’s Big Chance to Lower Drug Prices
A decision on whether to open a costly cancer drug to generic competition will be made shortly. It doesn’t require congressional approval.
Posted inEconomic Policy
China: Epicenter of the Supply Chain Crisis
How concentrating dependence on China upended our economy and added risk
Posted inTAP
Biden’s Executive Actions to Protect Workers
Today on TAP: The president could be doing a lot more with his executive power.
Posted inMoney, Politics, and Power
Rollups: The Emerging Magic Mushroom Monopoly
Compass Pathways has been aggressively using patent claims to corner the market on psychedelic-assisted treatments.